The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
New Insights Into the Pathogenesis of Alzheimer's Disease
Open accessAbstract
Alzheimer's disease (AD), a common neurodegenerative disease in the elderly and the most prevalent cause of dementia, is characterized by progressive cognitive impairment. The prevalence of AD continues to increase worldwide, becoming a great healthcare challenge of the twenty-first century. In the more than 110 years since AD was discovered, many related pathogenic mechanisms have been proposed, and the most recognized hypotheses are the amyloid and tau hypotheses. However, almost all clinical trials targeting these mechanisms have not identified any effective methods to treat AD. Scientists are gradually moving away from the simple assumption, as proposed in the original amyloid hypothesis, to new theories of pathogenesis, including gamma oscillations, prion transmission, cerebral vasoconstriction, growth hormone secretagogue receptor 1α (GHSR1α)-mediated mechanism, and infection. To place these findings in context, we first reviewed the neuropathology of AD and further discussed new insights in the pathogenesis of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Urnowey, S., Ansai, T., Bitko, V., Nakayama, K., Takehara, T., & Barik, S. (2006) · BMC Microbiology · doi:10.1186/1471-2180-6-26 · Cited by 75
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Glenner, G. G., & Wong, C. W. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(84)80190-4 · Cited by 5,404
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Apolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
The molecular pathology of Alzheimer's disease
Selkoe, D. J. (1991) · Neuron · doi:10.1016/0896-6273(91)90052-2 · Cited by 2,708
Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599
Amyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“The amyloid hypothesis was first proposed by John Hardy and David Allsop in 1991 (20).”
BackgroundKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188
Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3333 · Cited by 1,966
Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease
Butterfield, D. A., & Halliwell, B. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0132-6 · Cited by 1,954 · cited 1×
“There are many hypotheses to explain AD pathogenesis, involving the amyloid cascade (16), tau hyperphosphorylation (17), neurotransmitters, and oxidative stress (18).”
Background2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Brookmeyer, R., Gray, S., & Kawas, C. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.9.1337 · Cited by 1,787
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Gamma frequency entrainment attenuates amyloid load and modifies microglia
Iaccarino, H. F., Singer, A. C., Martorell, A. J., Rudenko, A., Gao, F., Gillingham, T. Z., Mathys, H., Seo, J., Kritskiy, O., Abdurrob, F., et al. (2016) · Nature · doi:10.1038/nature20587 · Cited by 1,328
ABAD Directly Links Aß to Mitochondrial Toxicity in Alzheimer's Disease
Lustbader, J. W., Cirilli, M., Lin, C., Xu, H. W., Takuma, K., Wang, N., Caspersen, C., Chen, X., Pollak, S., Chaney, M., et al. (2004) · Science · doi:10.1126/science.1091230 · Cited by 1,303
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Network abnormalities and interneuron dysfunction in Alzheimer disease
Palop, J. J., & Mucke, L. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.141 · Cited by 1,022
Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment
Scheff, S. W., Price, D. A., Schmitt, F. A., & Mufson, E. J. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.09.012 · Cited by 1,017 · cited 1×
“Hippocampal lesions are one of the earliest lesions to appear in AD and affect cognitive function (100), which may be related to GHSR1α.”
BackgroundDifferential Regulation of Dynein and Kinesin Motor Proteins by Tau
Dixit, R., Ross, J. L., Goldman, Y. E., & Holzbaur, E. L. F. (2008) · Science · doi:10.1126/science.1152993 · Cited by 1,012 · cited 1×
“function (57, 58), maintain synaptic structure and function (59), and regulate neuronal signaling.”
BackgroundRoles of tau protein in health and disease
Guo, T., Noble, W., & Hanger, D. P. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1707-9 · Cited by 1,003
Li, S., Hong, S., Shepardson, N. E., Walsh, D. M., Shankar, G. M., & Selkoe, D. (2009) · Neuron · doi:10.1016/j.neuron.2009.05.012 · Cited by 972
A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease
Panza, F., Lozupone, M., Logroscino, G., & Imbimbo, B. P. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0116-6 · Cited by 965
Ghrelin controls hippocampal spine synapse density and memory performance
Diano, S., Farr, S. A., Benoit, S. C., McNay, E. C., da Silva, I., Horvath, B., Gaskin, F. S., Nonaka, N., Jaeger, L. B., Banks, W. A., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1656 · Cited by 828 · cited 1×
“GHSR1α dysregulation also has a huge impact on hippocampal metabolic processes and calcium signaling, which is closely related to synaptic activity and hippocampal-dependent memory impairment in elderly and AD patients (105).”
BackgroundMulti-sensory Gamma Stimulation Ameliorates Alzheimer’s-Associated Pathology and Improves Cognition
Martorell, A. J., Paulson, A. L., Suk, H.-J., Abdurrob, F., Drummond, G. T., Guan, W., Young, J. Z., Kim, D. N.-W., Kritskiy, O., Barker, S. J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.014 · Cited by 798
The Genetics of Alzheimer's Disease
Bertram, L., & Tanzi, R. E. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00008-4 · Cited by 760
The genetics of Alzheimer disease
Tanzi, R. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006296 · Cited by 727
Wong, G. T., Manfra, D., Poulet, F. M., Zhang, Q., Josien, H., Bara, T., Engstrom, L., Pinzon-Ortiz, M., Fine, J. S., Lee, H.-J. J., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311652200 · Cited by 718
Randomized trial of verubecestat for mild-to-moderate Alzheimer's disease
Egan, M. F., Kost, J., Tariot, P. N., Aisen, P. S., Cummings, J. L., Vellas, B., Sur, C., Mukai, Y., Voss, T., Furtek, C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1706441 · Cited by 685
Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action.
Bollag, D. M., McQueney, P. A., Zhu, J., Hensens, O. D., Koupal, L. R., Liesch, J. M., Goetz, M., Lazarides, E., & Woods, C. M. (1995) · PubMed · Cited by 685
Amyloid β oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes
Nortley, R., Korte, N., Izquierdo, P., Hirunpattarasilp, C., Mishra, A., Jaunmuktane, Z., Kyrargyri, V., Pfeiffer, T., Khennouf, L., Madry, C., et al. (2019) · Science · doi:10.1126/science.aav9518 · Cited by 682 · cited 4×
“The vasoconstrictionmechanism described suggests that there are some potential therapies for the early treatment of AD, such as the NOX4 inhibitor GKT137831 and the vasodilator C-type natriuretic peptide (CNP) (111), which can prevent the contraction of blood vessels.”
BackgroundInfluentialEimer, W. A., Vijaya Kumar, D. K., Navalpur Shanmugam, N. K., Rodriguez, A. S., Mitchell, T., Washicosky, K. J., György, B., Breakefield, X. O., Tanzi, R. E., & Moir, R. D. (2018) · Neuron · doi:10.1016/j.neuron.2018.06.030 · Cited by 674
Schneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Alzheimer’s Disease: Past, Present, and Future
Bondi, M. W., Edmonds, E. C., & Salmon, D. P. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s135561771700100x · Cited by 649
Dickey, C. A., Kamal, A., Lundgren, K., Klosak, N., Bailey, R. M., Dunmore, J., Ash, P., Shoraka, S., Zlatkovic, J., Eckman, C. B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29715 · Cited by 642
Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression
Sun, X., He, G., Qing, H., Zhou, W., Dobie, F., Cai, F., Staufenbiel, M., Huang, L. E., & Song, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606298103 · Cited by 605 · cited 1×
“Animal studies have also found that exogenous Aβ can reduce cerebral blood flow in rats (109), which in turn promotes Aβ production (110).”
BackgroundStructural characterization of the core of the paired helical filament of Alzheimer disease.
Wischik, C. M., Novak, M., Edwards, P. C., Klug, A., Tichelaar, W., & Crowther, R. A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.13.4884 · Cited by 595
Milano, J., McKay, J., Dagenais, C., Foster-Brown, L., Pognan, F., Gadient, R., Jacobs, R. T., Zacco, A., Greenberg, B., & Ciaccio, P. J. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh254 · Cited by 576
Neve, R. L., Harris, P., Kosik, K. S., Kurnit, D. M., & Donlon, T. A. (1986) · Molecular Brain Research · doi:10.1016/0169-328x(86)90033-1 · Cited by 565
Randomized trial of verubecestat for prodromal Alzheimer's disease
Egan, M. F., Kost, J., Voss, T., Mukai, Y., Aisen, P. S., Cummings, J. L., Tariot, P. N., Vellas, B., van Dyck, C. H., Boada, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812840 · Cited by 545
Update on Alzheimer’s Disease Therapy and Prevention Strategies
Graham, W. V., Bonito-Oliva, A., & Sakmar, T. P. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-103753 · Cited by 506
Geling, A., Steiner, H., Willem, M., Bally‐Cuif, L., & Haass, C. (2002) · The EMBO Reports · doi:10.1093/embo-reports/kvf124 · Cited by 497
A Unifying Role for Prions in Neurodegenerative Diseases
Prusiner, S. B. (2012) · Science · doi:10.1126/science.1222951 · Cited by 491
Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection
Adaikkan, C., Middleton, S. J., Marco, A., Pao, P.-C., Mathys, H., Kim, D. N.-W., Gao, F., Young, J. Z., Suk, H.-J., Boyden, E. S., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.04.011 · Cited by 469
Periodontitis and Cognitive Decline in Alzheimer’s Disease
Ide, M., Harris, M., Stevens, A., Sussams, R., Hopkins, V., Culliford, D., Fuller, J., Ibbett, P., Raybould, R., Thomas, R., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151081 · Cited by 461 · cited 1×
“A prospective study supported that cognitive function in patients with active CP was significantly reduced within 6 months compared with AD patients without active CP (117).”
ResultThe Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · cited 1×
“In 2011, Ferreira officially proposed the “Aβ oligomer pathogenic theory,” suggesting that soluble Aβ oligomers are the initiating factors leading to a series of pathological changes in AD (30).”
BackgroundGauthier, S., Feldman, H. H., Schneider, L. S., Wilcock, G. K., Frisoni, G. B., Hardlund, J. H., Moebius, H. J., Bentham, P., Kook, K. A., Wischik, D. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31275-2 · Cited by 427
Tau impairs neural circuits, dominating amyloid-β effects, in Alzheimer models in vivo
Busche, M. A., Wegmann, S., Dujardin, S., Commins, C., Schiantarelli, J., Klickstein, N., Kamath, T. V., Carlson, G. A., Nelken, I., & Hyman, B. T. (2019) · Nature Neuroscience · doi:10.1038/s41593-018-0289-8 · Cited by 413
Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease
McGeer, P. L., & Rogers, J. (1992) · Neurology · doi:10.1212/wnl.42.2.447 · Cited by 406
Butterfield, D. A., & Boyd-Kimball, D. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170543 · Cited by 403
Gamma Oscillations in the Hippocampus
Colgin, L. L., & Moser, E. I. (2010) · Physiology · doi:10.1152/physiol.00021.2010 · Cited by 383
Synaptic plasticity of NMDA receptors: mechanisms and functional implications
Hunt, D. L., & Castillo, P. E. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2012.01.007 · Cited by 382
Takeda, S., Wegmann, S., Cho, H., DeVos, S. L., Commins, C., Roe, A. D., Nicholls, S. B., Carlson, G. A., Pitstick, R., Nobuhara, C. K., et al. (2015) · Nature Communications · doi:10.1038/ncomms9490 · Cited by 371
Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage
Shafiei, S. S., Guerrero-Muñoz, M. J., & Castillo-Carranza, D. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00083 · Cited by 314
Genes associated with Alzheimer's disease: an overview and current status
Giri, M., Lü, Y., & Zhang, M. (2016) · Clinical Interventions in Aging · doi:10.2147/cia.s105769 · Cited by 311
Microtubule-associated protein tau is essential for long-term depression in the hippocampus
Kimura, T., Whitcomb, D. J., Jo, J., Regan, P., Piers, T., Heo, S., Brown, C., Hashikawa, T., Murayama, M., Seok, H., et al. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0144 · Cited by 307
McConlogue, L., Buttini, M., Anderson, J. P., Brigham, E. F., Chen, K. S., Freedman, S. B., Games, D., Johnson-Wood, K., Lee, M., Zeller, M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611687200 · Cited by 300
Kaushal, V, Dye, R., Pakavathkumar, P., Foveau, B., Flores, J., Hyman, B., Ghetti, B., Koller, B. H., & LeBlanc, A. C. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.16 · Cited by 297 · cited 1×
“Infection Mechanism in AD The brain tissue of AD patients exhibits inflammation, such as the activation of complement system factors and microglia (112).”
BackgroundMocanu, M.-M., Nissen, A., Eckermann, K., Khlistunova, I., Biernat, J., Drexler, D., Petrova, O., Schönig, K., Bujard, H., Mandelkow, E., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2824-07.2008 · Cited by 297
Ye, S., Huang, Y., Müllendorff, K., Dong, L., Giedt, G., Meng, E. C., Cohen, F. E., Kuntz, I. D., Weisgraber, K. H., & Mahley, R. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508693102 · Cited by 275
Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274
Periodontal disease associates with higher brain amyloid load in normal elderly
Kamer, A. R., Pirraglia, E., Tsui, W., Rusinek, H., Vallabhajosula, S., Mosconi, L., Yi, L., McHugh, P., Craig, R. G., Svetcov, S., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.038 · Cited by 268
Self-citationGoutagny, R., Gu, N., Cavanagh, C., Jackson, J., Chabot, J., Quirion, R., Krantic, S., & Williams, S. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12233 · Cited by 267
Quantitative imaging of energy expenditure in human brain
Zhu, X.-H., Qiao, H., Du, F., Xiong, Q., Liu, X., Zhang, X., Ugurbil, K., & Chen, W. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.02.013 · Cited by 265
Zlokovic, B. V., Deane, R., Sagare, A. P., Bell, R. D., & Winkler, E. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.07002.x · Cited by 261
Memantine for Alzheimer’s Disease: An Updated Systematic Review and Meta-analysis
Kishi, T., Matsunaga, S., Oya, K., Nomura, I., Ikuta, T., & Iwata, N. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170424 · Cited by 249
Poole, S., Singhrao, S. K., Chukkapalli, S., Rivera, M., Velsko, I., Kesavalu, L., & Crean, S. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-140315 · Cited by 215
Morbus Alzheimer and Morbus Pick: A Genetic, Clinical and Patho-anatomical Study
(1953) · AIBS Bulletin · doi:10.1093/aibsbulletin/3.2.16-c · Cited by 208
The Role of Caspase Cleavage of Tau in Alzheimer Disease Neuropathology
Cotman, C. W., Poon, W. W., Rissman, R. A., & Blurton-Jones, M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.104 · Cited by 199
Identification of β-Secretase (BACE1) Substrates Using Quantitative Proteomics
Hemming, M. L., Elias, J. E., Gygi, S. P., & Selkoe, D. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008477 · Cited by 194
Gillespie, A. K., Jones, E. A., Lin, Y.-H., Karlsson, M. P., Kay, K., Yoon, S. Y., Tong, L. M., Nova, P., Carr, J. S., Frank, L. M., et al. (2016) · Neuron · doi:10.1016/j.neuron.2016.04.009 · Cited by 187
Hudry, E., Dashkoff, J., Roe, A. D., Takeda, S., Koffie, R. M., Hashimoto, T., Scheel, M., Spires-Jones, T., Arbel-Ornath, M., Betensky, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007000 · Cited by 187
Presenilin-dependent γ-secretase activity modulates thymocyte development
Doerfler, P., Shearman, M. S., & Perlmutter, R. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161102498 · Cited by 178
Type 1 diabetes exaggerates features of Alzheimer's disease in APP transgenic mice
Jolivalt, C. G., Hurford, R., Lee, C. A., Dumaop, W., Rockenstein, E., & Masliah, E. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.11.005 · Cited by 177
APOE ε2 is associated with milder clinical and pathological Alzheimer disease
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176
Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice
Stöhr, J., Condello, C., Watts, J. C., Bloch, L., Oehler, A., Nick, M., DeArmond, S. J., Giles, K., DeGrado, W. F., & Prusiner, S. B. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408968111 · Cited by 176
Barten, D. M., Fanara, P., Andorfer, C., Hoque, N., Wong, P. Y. A., Husted, K. H., Cadelina, G. W., DeCarr, L. B., Yang, L., Liu, V., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.0188-12.2012 · Cited by 173
Asllani, I., Habeck, C., Scarmeas, N., Borogovac, A., Brown, T. R., & Stern, Y. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600570 · Cited by 172 · cited 1×
“In early AD, angiogenesis damage and cerebral blood flow decrease, which are thought to be the first changes of AD (108).”
BackgroundGenetics of Alzheimer's disease: new evidences for an old hypothesis?
Lambert, J., & Amouyel, P. (2011) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2011.02.002 · Cited by 171
Burstein, A. H., Sabbagh, M., Andrews, R., Valcarce, C., Dunn, I., & Altstiel, L. (2018) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2018.18 · Cited by 171
Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
Hölttä, M., Hansson, O., Andréasson, U., Hertze, J., Minthon, L., Nägga, K., Andreasen, N., Zetterberg, H., & Blennow, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066381 · Cited by 168
The Growth Hormone Secretagogue Receptor: Its Intracellular Signaling and Regulation
Yin, Y., Li, Y., & Zhang, W. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034837 · Cited by 162
Shea, D. W., Hsu, C.-C., Bi, T., Paranjapye, N., Childers, M. C., Cochran, J., Tomberlin, C., Wang, L., Paris, D., Zonderman, J. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1820585116 · Cited by 154
Aβ and tau prion-like activities decline with longevity in the Alzheimer’s disease human brain
Aoyagi, A., Condello, C., Stöhr, J., Yue, W., Rivera, B. M., Lee, J. C., Woerman, A. L., Halliday, G. M., van Duinen, S. G., Ingelsson, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat8462 · Cited by 144
Tau: The Center of a Signaling Nexus in Alzheimer's Disease
Khan, S. S., & Bloom, G. S. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00031 · Cited by 143
Wu, Y., Du, S., Johnson, J. L., Tung, H.-Y., Landers, C. T., Liu, Y., Seman, B. G., Wheeler, R. T., Costa-Mattioli, M., Kheradmand, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07991-4 · Cited by 143
Mably, A. J., Gereke, B. J., Jones, D. T., & Colgin, L. L. (2016) · Hippocampus · doi:10.1002/hipo.22697 · Cited by 142
Impaired Hippocampal Neurogenesis and its Enhancement with Ghrelin in 5XFAD Mice
Moon, M., Cha, M.-Y., & Mook‐Jung, I. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-132417 · Cited by 138
Hippocampal dopamine/DRD1 signaling dependent on the ghrelin receptor
Kern, A., Mavrikaki, M., Ullrich, C., Albarran-Zeckler, R., Brantley, A. F., & Smith, R. G. (2015) · Cell · doi:10.1016/j.cell.2015.10.062 · Cited by 136 · cited 2×
“Moreover, GHSR1α plays a role in hippocampal synaptic physiology and memory maintenance by regulating the dopamine receptor D1 (DRD1) to activate Ca2+/calmodulin-dependent protein kinase II (CaMKII) via the non-canonical Gαq-Ca2+ signaling pathway (97, 99).”
BackgroundAmyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo
Vergara, C., Houben, S., Suain, V., Yilmaz, Z., Decker, R. D., Dries, V. V., Boom, A., Mansour, S., Leroy, K., Ando, K., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1953-5 · Cited by 133
Callahan, L. M., Vaules, W. A., & Coleman, P. D. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199903000-00007 · Cited by 130
In vivo inhibition of Aβ production by memapsin 2 (β‐secretase) inhibitors
Chang, W., Koelsch, G., Wong, S., Downs, D., Da, H., Weerasena, V., Gordon, B., Devasamudram, T., Bilcer, G. M., Ghosh, A. K., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02452.x · Cited by 120
Coronel, R., Bernabeu-Zornoza, A., Palmer, C., Moreno, M. D. M. M., Zambrano, A., Cano, E., & Liste, I. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0914-2 · Cited by 117
Soluble Alzheimers β-amyloid constricts the cerebral vasculature in vivo
Suo, Z., Humphrey, J., Kundtz, A., Sethi, F. N., Placzek, A. N., Crawford, F., & Mullan, M. (1998) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00814-3 · Cited by 114
Brodbeck, J., McGuire, J., Liu, Z., Meyer-Franke, A., Balestra, M. E., Jeong, D.-E., Pleiss, M., McComas, C., Hess, F., Witter, D., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.217380 · Cited by 113
Morbus Alzheimer and Morbus Pick.
KALMUS, H., Sjogren, T., Sjögren, H., & Lindgren, Å. G. H. (1953) · Population Studies · doi:10.2307/2172384 · Cited by 109
Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Condello, C., & Stöhr, J. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.03.014 · Cited by 108
Somatostatin and Alzheimer's disease
Burgos‐Ramos, E., Hervás‐Aguilar, A., Aguado‐Llera, D., Puebla‐Jiménez, L., Hernández‐Pinto, A. M., Barrios, V., & Arilla, E. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.01.014 · Cited by 99
Booth, C. A., Witton, J., Nowacki, J., Tsaneva-Atanasova, K. T., Jones, M. W., Randall, A. D., & Brown, J. T. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.2151-15.2016 · Cited by 97
Morbus Alzheimer and Morbus Pick: A Genetic, Clinical and Patho-Anatomical Study.
(1953) · Archives of Internal Medicine · doi:10.1001/archinte.1953.00240180127021 · Cited by 96
Genetic ablation of tau improves mitochondrial function and cognitive abilities in the hippocampus
Jara, C., Aránguiz, A., Cerpa, W. F., Tapia‐Rojas, C., & Quintanilla, R. A. (2018) · Redox Biology · doi:10.1016/j.redox.2018.07.010 · Cited by 90
Boada, M., Brodaty, H., Cras, P. P., Balogiannis, S., Emre, M., Zhang, R. H., & Bahra, R. (2004) · Drugs & Aging · doi:10.2165/00002512-200421010-00004 · Cited by 87
Physiological and Pathophysiological Implications of Synaptic Tau
Regan, P. L., Whitcomb, D. J., & Cho, K. (2016) · The Neuroscientist · doi:10.1177/1073858416633439 · Cited by 82
Alzheimer’s disease: biological aspects, therapeutic perspectives and diagnostic tools
Carlo, M. D., Giacomazza, D., & Biagio, P. L. S. (2012) · Journal of Physics Condensed Matter · doi:10.1088/0953-8984/24/24/244102 · Cited by 78
Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 76
Pankiewicz, J. E., Guridi, M., Kim, J., Asuni, A. A., Sanchez, S., Sullivan, P. M., Holtzman, D. M., & Sadowski, M. J. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0075-0 · Cited by 74
Tian, J., Guo, L., Sui, S., Driskill, C., Phensy, A., Wang, Q., Gauba, E., Zigman, J. M., Swerdlow, R. H., Kroener, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav6278 · Cited by 72
Eslami, M., Sadeghi, B., & Goshadrou, F. (2018) · Hippocampus · doi:10.1002/hipo.23002 · Cited by 66
Association between apolipoprotein E polymorphism and Alzheimer disease in Tehran, Iran
Vaisi‐Raygani, A., Zahrai, M., Raygani, A. V., Doosti, M., Javadi, E., رضایی, م., & Pourmotabbed, T. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.073 · Cited by 65
Merck ends trial of potential Alzheimer’s drug verubecestat
Hawkes, N. (2017) · BMJ · doi:10.1136/bmj.j845 · Cited by 61
Zhou, R., Yang, G., & Shi, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1713605114 · Cited by 56
High Expression of Apolipoprotein E mRNA in the Brains with Sporadic Alzheimer’s Disease
Yamagata, K., Urakami, K., Ikeda, K., Ji, Y., Adachi, Y., Arai, H., Sasaki, H., Sato, K., & Nakashima, K. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051236 · Cited by 53
Hawkes, C. A., Deng, L., Shaw, J. E., Nitz, M., & McLaurin, J. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2009.07052.x · Cited by 53
Hippocampus ghrelin receptor signaling promotes socially-mediated learned food preference
Hsu, T. M., Noble, E. E., Reiner, D. J., Liu, C. M., Suarez, A. N., Konanur, V., Hayes, M. R., & Kanoski, S. E. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.039 · Cited by 53
Jeong, Y.-O., Shin, S. J., Park, J. Y., Ku, B. K., Song, J. S., Kim, J.-J., Jeon, S. G., Lee, S. M., & Moon, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061800 · Cited by 53
Truncated tau deregulates synaptic markers in rat model for human tauopathy
Jadhav, S., Katina, S., Kováč, A., Kazmerova, Z., Novák, M., & Žilka, N. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00024 · Cited by 45
Kinetics of human mutant tau prion formation in the brains of 2 transgenic mouse lines
Woerman, A. L., Patel, S., Kazmi, S. A., Oehler, A., Freyman, Y., Espiritu, L., Cotter, R., Castaneda, J. A., Olson, S. H., & Prusiner, S. B. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2822 · Cited by 44
Seminara, R. S., Jeet, C., Biswas, S., Kanwal, B., Iftikhar, W., Sakibuzzaman, M., & Rutkofsky, I. H. (2018) · Cureus · doi:10.7759/cureus.3285 · Cited by 43
It cuts two ways: microtubule loss during Alzheimer disease
Jean, D. C., & Baas, P. W. (2013) · EMBO Journal · doi:10.1038/emboj.2013.219 · Cited by 36
Cited by
Amyloid Beta in Aging and Alzheimer’s Disease
Sehar, U., Rawat, P., Reddy, A. P., Kopel, J., & Reddy, P. H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112924 · Cited by 361
Long Non-Coding RNA (lncRNA) Roles in Cell Biology, Neurodevelopment and Neurological Disorders
Aliperti, V., Skonieczna, J., & Cerase, A. (2021) · Non-Coding RNA · doi:10.3390/ncrna7020036 · Cited by 137
Wang, Z.-J., Li, X.-R., Chai, S.-F., Li, W.-R., Li, S., Hou, M., Li, J.-L., Ye, Y.-C., Cai, H.-Y., Hölscher, C., et al. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109716 · Cited by 125
De Simone, A., Tumiatti, V., Andrisano, V., & Milelli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00931 · Cited by 110
Microglia and Astrocytes in Alzheimer’s Disease: Significance and Summary of Recent Advances
Deng, Q., Wu, C., Parker, E., Liu, T. C.-Y., Duan, R., & Yang, L. (2023) · Aging and disease · doi:10.14336/ad.2023.0907 · Cited by 102
“…fragment, APPα, and a C-terminal fragment, C83. γ-secretase cleaves C83 into the nontoxic peptide P3 and the APP intracellular domain (AICD) [28, 29]. sAPPα and AICD support neurite outgrowth and the formation of learning and memory-related genes, providing neuroprotection for nerve cells…”
Background
Metadata
- Authors
- Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., Shi, C., & Xu, Y.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2020-01-10
- Volume
- 10
- Pages
- 1312-1312
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2998922852
- Cited by
- 344
- References
- 124
- FWCI
- 26.02
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.